An interventional study of Arm 1: Routine Care and Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection in Skin and Soft Tissue (SST) Infection, sponsored by Harvard Pilgrim Health Care. Completed at 102 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Harvard Pilgrim Health Care · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The INSPIRE Skin and Soft Tissue Infection trial is a cluster-randomized controlled trial of HCA Healthcare hospitals comparing routine empiric antibiotic stewardship practices with real-time, precision medicine computerized physician order entry (CPOE) smart prompts providing the probability that a non-critically ill adult admitted with skin and soft tissue infection is infected with a resistant pathogen.
Note: enrolled "subjects" represent 102 individual HCA Healthcare hospitals that have been randomized into 92 clusters. Hospitals were grouped into the same randomization cluster if they shared campuses or antibiotic stewardship staff.
2,097 studies on the registry are indexed under Infections; 361 are open to participants now.
This study's enrollment of 118,562 is above the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →Harvard Pilgrim Health Care is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Facility Inclusion Criteria:
Facility Exclusion Criteria:
-
Note: unit of randomization is the hospital, however the computerized physician order entry (CPOE) alert intervention will calculate risk estimates for adults age >=18 admitted to non-intensive care unit wards and who are ordered to receive extended-spectrum antibiotics for skin and soft tissue infection.
Continuation of routine antibiotic stewardship strategies.
Other: Arm 1: Routine Care
Use of computerized physician order entry (CPOE) smart prompts, clinician feedback, and activities to support CPOE adoption (including education and alignment of CPOE workflows) to guide empiric choice of antibiotics for skin/soft tissue infection in the first 3 days of hospitalization.
Other: Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection
Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having a skin/soft tissue infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
Extended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day
Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Extended-spectrum days-of-therapy per empiric day is defined as the summed number of different extended-spectrum antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute to the numerator and denominator. For example, 2 different extended-spectrum antibiotics administered at least once during each of the first 3 days would yield 6 days of extended-spectrum days-of-therapy.
Time frame: First 3 calendar days of hospitalization for each patient during the 12-month baseline and 12-month intervention periods
Antipseudomonal Antibiotic Days Of Therapy (ES-DOT) Per Empiric Day
Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Antipseudomonal days-of-therapy per empiric day is defined as the summed number of different antipseudomonal antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute to the numerator and denominator. For example, 2 different antipseudomonal antibiotics administered at least once during each of the first 3 days would yield 6 days of antipseudomonal days-of-therapy.
Time frame: First 3 calendar days of hospitalization for each patient during the 12-month baseline and 12-month intervention periods
Intensive Care Unit (ICU) Transfer [Safety Outcome 1]
Days from hospital admission until transfer to ICU, if that occurs. If it doesn't occur, the number of days is censored (capped) at the patient's hospital discharge or at the end of data collection. Almost all patients will be discharged before the end of trial data collection.
Time frame: Duration of hospitalization for each patient during 12-month baseline and 12-month intervention periods
Length-of-stay [Safety Outcome 2]
Days from hospital admission until discharge. If the patient remains in the hospital at the end of the trial data collection, the number of days is censored (capped) at that time. Almost all patients will be discharged before the end of trial data collection.
Time frame: Duration of hospitalization for each patient during 12-month baseline and 12-month intervention periods
Extended-Spectrum Days of Therapy With Inpatient Extended-Spectrum (ES) Antibiotic Treatment After Empiric Period
The number of different ES antibiotics received each day, on hospital days ≥4 and ≤14. Note: this outcome is intended for a secondary manuscript
Time frame: 12 months
Empiric and Total Antibiotic Costs
Empiric and total antibiotic costs for skin and soft tissue infection during hospitalization. Note: this outcome is intended for a secondary manuscript.
Time frame: 12 months
Incidence of Hospital-Onset C. Difficile
Hospital-onset C. difficile positive tests (specimen obtained) on hospital days ≥4 and ≤14. Note: this outcome is intended for a secondary manuscript.
Time frame: 12 months
Incidence of Hospital-Onset MDRO-Positive Cultures
Newly-detected hospital-onset MDRO-positive cultures on hospital days ≥4 and ≤14. Includes total MDRO and specific MDRO subsets. Note: this outcome is intended for a secondary manuscript.
Time frame: 12 months
92 out of 142 HCA Healthcare hospitals were recruited for this trial. There was a 12-month baseline period (January 1, 2019-December 31, 2019), 5-month phase-in (August 2, 2022-December 31, 2022), and 12-month intervention (January 1, 2023-December 31, 2023). Data from the phase-in period were excluded from all analyses (i.e., Baseline, Intervention, Outcome Measures, and Adverse Events).
| Milestone | Arm 1: Routine Stewardship | Arm 2: INSPIRE CPOE Bundle |
|---|---|---|
| Started | 29595 | 28242 |
| Completed | 29595 | 28242 |
| Not completed | 0 | 0 |
| Milestone | Arm 1: Routine Stewardship | Arm 2: INSPIRE CPOE Bundle |
|---|---|---|
| Started | 31337 | 29388 |
| Completed | 31337 | 29388 |
| Not completed | 0 | 0 |
Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Extended-spectrum days-of-therapy per empiric day is defined as the summed number of different extended-spectrum antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute to the numerator and denominator. For example, 2 different extended-spectrum antibiotics administered at least once during each of the first 3 days would yield 6 days of extended-spectrum days-of-therapy.
| Extended-Spectrum Days-of-Therapy | Arm 1: Routine Stewardship | Arm 2: INSPIRE CPOE Bundle |
|---|---|---|
| Baseline (12 months) | 43305 | 40156 |
| Intervention (12 months) | 43927 | 30287 |
Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Antipseudomonal days-of-therapy per empiric day is defined as the summed number of different antipseudomonal antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute to the numerator and denominator. For example, 2 different antipseudomonal antibiotics administered at least once during each of the first 3 days would yield 6 days of antipseudomonal days-of-therapy.
| Antipseudomonal Days-of-Therapy | Arm 1: Routine Stewardship | Arm 2: INSPIRE CPOE Bundle |
|---|---|---|
| Baseline (12 months) | 43305 | 38059 |
| Intervention (12 months) | 43927 | 30287 |
Days from hospital admission until transfer to ICU, if that occurs. If it doesn't occur, the number of days is censored (capped) at the patient's hospital discharge or at the end of data collection. Almost all patients will be discharged before the end of trial data collection.
| Days to event | Arm 1: Routine Stewardship | Arm 2: INSPIRE CPOE Bundle |
|---|---|---|
| Baseline (12 months) | 5.9 ± 2.8 | 6.1 ± 2.9 |
| Intervention (12 months) | 6.3 ± 3.2 | 6.3 ± 3.1 |
Days from hospital admission until discharge. If the patient remains in the hospital at the end of the trial data collection, the number of days is censored (capped) at that time. Almost all patients will be discharged before the end of trial data collection.
| Days to event | Arm 1: Routine Stewardship | Arm 2: INSPIRE CPOE Bundle |
|---|---|---|
| Baseline (12 months) | 6.2 ± 3.7 | 6.1 ± 3.6 |
| Intervention (12 months) | 6.5 ± 3.8 | 6.4 ± 3.8 |
The number of different ES antibiotics received each day, on hospital days ≥4 and ≤14. Note: this outcome is intended for a secondary manuscript
Results for this outcome have not been posted.
Empiric and total antibiotic costs for skin and soft tissue infection during hospitalization. Note: this outcome is intended for a secondary manuscript.
Results for this outcome have not been posted.
Hospital-onset C. difficile positive tests (specimen obtained) on hospital days ≥4 and ≤14. Note: this outcome is intended for a secondary manuscript.
Results for this outcome have not been posted.
Newly-detected hospital-onset MDRO-positive cultures on hospital days ≥4 and ≤14. Includes total MDRO and specific MDRO subsets. Note: this outcome is intended for a secondary manuscript.
Results for this outcome have not been posted.
Collected over 12 months (baseline), 12 months (intervention). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: Routine Stewardship | 0/60,932 (0%) | 0/60,932 (0%) | 0/60,932 (0%) |
| Arm 2: INSPIRE CPOE Bundle | 0/57,630 (0%) | 0/57,630 (0%) | 0/57,630 (0%) |
Overall number of participants reflects the total across baseline and intervention periods. 118,562 patients from 92 hospitals were randomized to a study group; Prior to the to start of the intervention period, 2 hospitals divested from the participating healthcare system, and thus were excluded from Arm 2: CPOE Bundle.
| Age, Continuous(years) | Arm 1: Routine Stewardship | Arm 2: INSPIRE CPOE Bundle | Total |
|---|---|---|---|
| Baseline (12 months) | 58 ± 18 | 58 ± 18 | 58 ± 18 |
| Intervention (12 months) | 59 ± 18 | 58 ± 17 | 59 ± 18 |
| Sex/Gender, Customized(Participants) | Arm 1: Routine Stewardship | Arm 2: INSPIRE CPOE Bundle | Total |
|---|---|---|---|
| Baseline (12 months) — Female | 13087 | 12377 | 25464 |
| Baseline (12 months) — Male | 16320 | 15719 | 32039 |
| Baseline (12 months) — Unknown | 188 | 146 | 334 |
| Intervention (12 months) — Female | 13356 | 17015 | 30371 |
| Intervention (12 months) — Male | 17979 | 12373 | 30352 |
| Intervention (12 months) — Unknown | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Arm 1: Routine Stewardship | Arm 2: INSPIRE CPOE Bundle | Total |
|---|---|---|---|
| Baseline (12 months) — Black | 3052 | 3638 | 6690 |
| Baseline (12 months) — White | 23153 | 20730 | 43883 |
| Baseline (12 months) — Other | 1246 | 687 | 1933 |
| Baseline (12 months) — Unknown | 2144 | 3187 | 5331 |
| Intervention (12 months) — Black | 3672 | 3989 | 7661 |
| Intervention (12 months) — White | 23385 | 20885 | 44270 |
| Intervention (12 months) — Other | 685 | 333 | 1018 |
| Intervention (12 months) — Unknown | 3595 | 4181 | 7776 |
Showing the first 100 of 102 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2023 to primary completion in May 2024, 16 months.
Results were first posted in Aug 2025, 1 year 3 months after primary completion.
Of 276 non-industry interventional studies with no phase under Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 51. This study's 16 months is below that.
Counting every sponsor, half of 308 studies reached it within 24 months; a quarter within 9 and three quarters within 48.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Harvard Pilgrim Health Care